Results
14
Smaller, under-the-radar companies, backed by insider buying, presenting a compelling opportunity for investors seeking undervalued gems.
14 companies
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
CDA | AU$12.79 | 3.6% | 61.5% | AU$2.3b | AU$11.42 | PE31x | E16.2% | 1.6% | Tech | ||
HLS | AU$1.47 | 3.5% | -48.4% | AU$1.1b | AU$1.41 | PB1x | E91.1% | 0% | Healthcare | ||
DDR | AU$10.45 | 1.9% | 25.8% | AU$1.9b | AU$10.79 | PE23x | E7.8% | 4.3% | Tech | ||
REP | AU$0.65 | 2.4% | -7.8% | AU$330.7m | n/a | PB1.4x | E112.0% | 8.3% | Real Estate | ||
CYG | AU$1.42 | 2.9% | 37.2% | AU$165.8m | AU$2.00 | PE297.7x | E82.3% | 2.5% | Capital Goods | ||
APE | AU$10.56 | 3.3% | -25.2% | AU$2.7b | AU$11.96 | PE9.7x | E-0.7% | 7.0% | Retail | ||
ELD | AU$9.33 | 0.5% | 46.9% | AU$1.5b | AU$8.83 | PE23.2x | E22.8% | 3.9% | Food, Beverage & Tobacco | ||
NEU | AU$15.56 | -4.1% | 26.8% | AU$2.0b | AU$26.54 | PE12.7x | E-10.1% | n/a | Pharmaceuticals & Biotech | ||
DRR | AU$3.68 | -3.7% | -19.7% | AU$2.0b | AU$4.49 | PE11.6x | E-8.1% | 8.6% | Materials | ||
KLS | AU$5.20 | 6.1% | -23.0% | AU$1.4b | AU$7.04 | PE47.3x | E25.5% | 3.4% | Transportation | ||
ACF | AU$1.07 | -0.9% | 17.6% | AU$322.5m | AU$1.36 | PE12.8x | E18.6% | 5.3% | Capital Goods | ||
PWR | AU$1.80 | 4.7% | -32.6% | AU$309.6m | AU$2.21 | PE6.5x | E-3.6% | 9.4% | Retail | ||
MFF | AU$3.85 | 1.9% | 32.3% | AU$2.2b | n/a | PE5x | n/a | 3.6% | Diversified Financials | ||
NWH | AU$3.53 | 11.7% | 30.7% | AU$1.6b | AU$3.78 | PE15.3x | E9.6% | 4.4% | Capital Goods |